Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Public ClinicalTrials.gov record NCT06450886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.
Study identification
- NCT ID
- NCT06450886
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 270 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2024
- Primary completion
- Dec 31, 2028
- Completion
- Mar 31, 2029
- Last update posted
- Jul 27, 2025
2024 – 2029
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neuromuscular Research Center | Phoenix | Arizona | 85028 | — |
| University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center | Irvine | California | 92868 | — |
| Keck Hospital of USC | Los Angeles | California | 90033 | — |
| Yale School of Medicine | New Haven | Connecticut | 06519 | — |
| Neuromuscular Diagnostic Center - Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Womens Hospital | Boston | Massachusetts | 021158 | — |
| Hospital for Special Surgery | New York | New York | 10021 | — |
| Duke Neurological Disorders Clinic | Durham | North Carolina | 27710 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Penn State Health Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Arthritis and Autoimmunity Center, Falk Clinic | Pittsburgh | Pennsylvania | 15213 | — |
| Austin Neuromuscular Center | Austin | Texas | 78759 | — |
| Texas Neurology | Dallas | Texas | 75206 | — |
| Nerve and Muscle Center of Texas | Houston | Texas | 75206 | — |
| Virginia Commonwealth University | Henrico | Virginia | 23233 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06450886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06450886 live on ClinicalTrials.gov.